Vanta Bioscience Share Price Today

Vanta Bioscience turns profitable in FY26 with revenue up ~61%

Standalone PAT turned to Rs. 1,198.11 thousand in FY26 from a loss of Rs. 26,594.08 thousand in FY25. Standalone revenue from operations rose approximately 61.11% to Rs. 18,163.64 thousand in FY26 from Rs. 11,274.22 thousand in FY25. 8,00,000 equity shares allotted on preferential basis at Rs. 10/- face value and Rs. 40/- premium, raising paid-up capital to Rs. 7,11,20,000/-. 10th AGM scheduled for September 30, 2026; re-appointment of Managing Director Dopesh Raja Mulakala for three years proposed at up to Rs. 2,50,000/- per month. Auditors flagged non-provision for gratuity and outstanding statutory dues; subsidiary Vanta Clinical Research Limited yet to commence operations.

Vanta warns of AI security chaos as employee builder roles surge 300%

Builder roles at Vanta customers surged more than 300% YoY as AI democratizes software development. Vanta identifies 'shadow AI' as a key risk where unvetted tools access corporate data. Daily users of Vanta's AI agent grew more than 250% this year. Usage of Vanta's MCP server expanded 50-fold, indicating high demand for automated workflows.

Vanta achieves FedRAMP 20x Class C Certification for Government Cloud

Vanta has achieved FedRAMP 20x Class C Certification for its Government Cloud offering, enabling federal agencies to use its automated trust management platform for continuous compliance. The certification supports IT modernization and resiliency requirements. Carahsoft Technology Corp distributes Vanta's solutions through multiple government contract vehicles.

Vanta Bioscience board to consider FY26 audited results on May 30

Vanta Bioscience Limited's board is set to meet on May 30, 2026, to approve the audited financial results for the financial year and half year ended March 31, 2026. The meeting will also review the statutory auditors' reports. The trading window for designated personnel remains closed from April 01, 2026, to June 1, 2026.

Vanta Bioscience Limited Submits SEBI Compliance Certificate for Q4FY26

Vanta Bioscience Limited submitted its SEBI compliance certificate for Q4FY26 to BSE Limited on April 10, 2026. The company's RTA, Bigshare Services Private Ltd., confirmed that Regulation 74(5) is not applicable as the entire shareholding remains in demat form with no rematerialisation or dematerialisation requests during the quarter. This submission fulfills the company's regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018.

Vanta Bioscience Limited Responds to BSE Inquiry on Share Price Movement

Vanta Bioscience Limited has clarified to BSE Limited that recent share price movements are market-driven, following a regulatory inquiry dated 25.02.2026. The company confirmed compliance with SEBI Listing Regulations and stated that all material information affecting operations has been disclosed within required timeframes. Management emphasized they are unaware of specific reasons for price movement and reiterated commitment to regulatory compliance.